FGF21 and metabolic dysfunction-associated steatotic liver disease: Beyond the known altered levels of the protective adipokine adiponectin in metabolic diseases, abnormal secretion of hepatokines such as FGF21 and fetuin-A in response to metabolic stress has been shown to disrupt insulin signaling, glucose and lipid metabolism, inflammation, and lipotoxicity, contributing to the development and progression of MASLD.